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phoshorylation by augmenting Lyn kinase activity, while CD22 inhibits CD19 phosphorylation via SHP-1. Importantly, these molecules consisting of this "CD19/CD22
loop" are significantly related with autoimmune phenotype in mice. Thus, CD19/CD22 loop may be a potential therapeutic target in autoimmune disease by modulating B cell signaling.
Introduction
Recent studies have revealed that B lymphocytes have more diverse functions in the immune system than were appreciated (1) . Disruption of these functions leads to autoimmunity, in which B cells do not merely serve as passive producers of autoantibodies but also play a pivotal role via nonconventional mechanisms, including antigen presentation, cytokine production, and modulation of other immune cells. These (4) . By contrast, CD22, CD72, and FcγRIIb provide negative feedback pathways to downregulate BCR signaling through the recruitment of tyrosine phosphatases including SHP-1 and/or SHIP (5, 6) . Altering expression/function of these signaling components in mice can lead to autoimmune phenotypes. For example, a deficiency of Lyn, a Src-family PTK, leads to a severe lupus-like autoimmunity. This is likely to result from a failure of inhibitory feedback loops in which Lyn phosphorylates CD22 and CD72, triggering recruitment of SHP-1 to the plasma membrane, which then dampens BCR and/or CD19 signaling (5). Lyn deficiency also compromises an inhibitory pathway involving FcγRIIb and SHIP. In human, genetic and/or functional abnormalities have been found in these B cell signaling molecules as well. Herein we will discuss our current understanding of the molecular mechanisms of how B cell signaling components, especially CD19 and CD22, govern the emergence and intensity of BCR-mediated signals, and of how alterations in these tightly controlled regulatory activities contribute to autoimmunity in mice and humans. Precise understanding of these mechanisms will enable us to develop new therapeutic approaches of targeting specific components in B cell signaling pathways that govern the autoimmunity. This review focuses on recent advances in B cell signaling and autoimmune diseases, especially in terms with CD19 and CD22.
Roles of B cells in autoimmune diseases
It is widely accepted that antibodies (Abs) produced by autoreactive B cells can directly contribute to the pathogenesis in various autoimmune diseases. This is especially obvious in organ-specific autoimmune diseases such as pemphigus in dermatology field. For example, production of anti-desmoglein Ab in pemphigus directly causes interference of keratinocyte adhesion, resulting in blister formation. In systemic autoimmune diseases, autoantibodies can also play a pathogenic role (1) . In systemic lupus erythematosus 
B cell signaling and response regulators
To facilitate protective immunity to pathogens while avoiding self-reactivity and autoimmunity, B cell responses to antigens are tightly regulated through intracellular signaling pathways. Importantly, this balanced regulation is achieved by signals generated through BCR and other cell-surface molecules that provide a context in the specific circumstances. Such response regulators can either positively or negatively regulate the context of BCR signaling, and thus establish signaling thresholds that control the magnitude and duration of B cell activation. Positive response regulators that augment signals through BCR include CD19, while CD22, CD72, and FcγRIIb are among negative response regulators that dampen BCR signals (2, 16) (Fig. 2) .
CD19: a positive response regulator
CD19 serves as a major positive response regulator in B cells. CD19 expression is restricted to the B cell lineage and follicular dendritic cells which function as antigen-presenting cells located in the murine spleen. CD19 is a 95-kDa immunoglobulin (Ig) superfamily member which has an extracellular region consisted of two C2-type Ig-like domains and a cytoplasmic region of ~240 amino acids including 9 conserved tyrosine residues. On B cell surface, CD19 forms a complex with CD21, CD81, and Leu-13 (CD225). CD21 is a receptor for complement C3 cleavage fragments and Epstain-Bar virus. Upon CD21 ligation, CD19 serves as a signal-transducing element of the complex. CD81 expression is critical for optimal CD19 expression and localization within lipid rafts (17) . Accordingly, CD81-deificent mice exhibit a phenotype which resembles but is milder than that of CD19-deficient (CD19 -/-) mice (18) .
The cytoplasmic region of CD19 contains 9 tyrosines, which are critical for CD19 function as a signaling molecule. While CD19 does not have enzymatic activity, CD19 acts as a cell-surface adapter protein that recruits signaling molecules through the interaction with phosphoryated tyrosines. CD19 tyrosines are phosphorylated by Lyn, a dominant Src-family PTK member in B cells (19, 20) . CD19 regulates a variety of extracellular stimuli since CD19 is phosphorylated not only upon CD19/CD21 ligation but also BCR, CD38, CD40, or CD72 ligation as well as lipopolysaccharide stimulation itself is a primary target of CD22/SHP-1.
Switching off CD22 negative pathway by CD19
While CD19 can function independent of the ligation of CD19 itself, co-engagement of A mechanism for augmented signaling by simultaneous BCR and CD19
ligation is explained by a finding that simultaneous BCR and CD19 ligation inhibits tyrosine phosphorylation of CD22, as well as SHP-1 recruitment to phosphorylated CD22 (37, 38) . Thus, activation occurs without engagement of CD22 inhibitory pathway.
Simultaneous CD19 and BCR engagement may sequester the functionally available pool of Lyn away from CD22. Especially, the spatial relationship between the BCR, CD19 and CD22 is likely to be important to this process since CD22 locates outside of lipid rafts. (43) . Therefore, this "CD19/CD22 autoimmune loop" may be a potential therapeutic target in autoimmune disorders.
Tight-skin mouse and CD19/CD22 autoimmune loop
The Tight-skin (TSK) mouse, originally identified as a spontaneous mutation, is an animal model for human systemic sclerosis (SSc) (44) . A tandem duplication within the fibrillin 1 gene is considered to responsible for the TSK phenotype (45) . 
Conclusion
Therapy using anti-CD20 Ab in human autoimmune diseases have elucidated pathogenic roles of B cells in various aspects and have provided a new paradigm how to treat them. Mice and human abnormalities of each molecule that are related to autoimmunity are shown in the square.
